ASH® 2025 Highlights: Presenter Vignette – Alex Herrera
Alex Herrera
MD
City of Hope Medical Center
151
3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.
